Synergy Pharmaceuticals Inc (SGYP)

4.69
0.09 1.88
NASDAQ : Health Care
Prev Close 4.78
Open 4.80
Day Low/High 4.59 / 4.86
52 Wk Low/High 2.50 / 9.76
Volume 7.97M
Avg Volume 6.88M
Exchange NASDAQ
Shares Outstanding 223.12M
Market Cap 1.02B
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors

Answering questions from the Biotech Mailbag on FLXN and SGYP.

Synergy Pharmaceuticals To Present At Oppenheimer 27th Annual Healthcare Conference

Synergy Pharmaceuticals To Present At Oppenheimer 27th Annual Healthcare Conference

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that Marino Garcia, the company's EVP and Chief Strategy Officer, will present a corporate update at the Oppenheimer 27 th Annual Healthcare Conference on...

Synergy Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results And Business Update

Synergy Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results And Business Update

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for...

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Synergy Pharmaceuticals To Present At Leerink Partners 6th Annual Global Healthcare Conference

Synergy Pharmaceuticals To Present At Leerink Partners 6th Annual Global Healthcare Conference

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Marino Garcia, the company's EVP and Chief Strategy Officer, will participate in a fireside chat at Leerink Partners 6 th Annual Global Healthcare Conference...

Pivotal Phase 3 Data Results For TRULANCE™ (plecanatide) In The Treatment Of Chronic Idiopathic Constipation (CIC) Published In American Journal Of Gastroenterology

Pivotal Phase 3 Data Results For TRULANCE™ (plecanatide) In The Treatment Of Chronic Idiopathic Constipation (CIC) Published In American Journal Of Gastroenterology

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the American Journal of Gastroenterology has published detailed results from a pivotal Phase 3 trial that demonstrated the efficacy and safety of...

Synergy, Portola Still in My Sights

Synergy, Portola Still in My Sights

Both pharma companies are promising names that easily could become buyout targets.

How to Trade Hot Stocks Apple, Seadrill, Advanced Micro Devices

How to Trade Hot Stocks Apple, Seadrill, Advanced Micro Devices

Here's how to trade seven of the most active stocks on the market on Wednesday afternoon.

Premarket Biotech Movers: Synergy, Arrowhead, BioCryst

Premarket Biotech Movers: Synergy, Arrowhead, BioCryst

Synergy Pharmaceuticals, Arrowhead Pharmaceuticals and BioCryst Pharmaceuticals were among the biotech stock movers in premarket trading on Wednesday.

Synergy Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Synergy Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced the pricing of its underwritten public...

Synergy Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Synergy Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced an agreement to sell $125 million of...

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

First Week of SGYP March 17th Options Trading

First Week of SGYP March 17th Options Trading

Investors in Synergy Pharmaceuticals Inc saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGYP options chain for the new March 17th contracts and identified one put and one call contract of particular interest.

Bristol-Myers Squibb, Merck, Synergy Pharmaceuticals: Doug Kass' Views

Bristol-Myers Squibb, Merck, Synergy Pharmaceuticals: Doug Kass' Views

Doug Kass shares his thoughts on biotech and discusses the shape of things to come.

Synergy Pharmaceuticals Secures Approval for Linzess Competitor

Synergy Pharmaceuticals Secures Approval for Linzess Competitor

New bowel drug Trulance will be available for patients later this quarter.

Futures, Asia Mixed as Investors Ponder the New President

Futures, Asia Mixed as Investors Ponder the New President

Many are ready to seal in gains as Donald Trump becomes the 45th president of these United States.

Synergy Pharmaceuticals' TRULANCE™ (Plecanatide) Receives U.S. FDA Approval For The Treatment Of Adults With Chronic Idiopathic Constipation

Synergy Pharmaceuticals' TRULANCE™ (Plecanatide) Receives U.S. FDA Approval For The Treatment Of Adults With Chronic Idiopathic Constipation

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the U.

Biotech Sector to See M&A, Earnings Action

Biotech Sector to See M&A, Earnings Action

Deals already are popping up, and we'll soon have earnings reports from the industry giants.

Western Digital, Twilio, AT&T: 'Mad Money' Lightning Round (Friday 1/6/17)

Western Digital, Twilio, AT&T: 'Mad Money' Lightning Round (Friday 1/6/17)

Jim Cramer is bullish on Western Digital, Twilio, Salesforce.com and AT&T.

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)

Jim Cramer says he's focusing on health-care companies that will break news that moves stocks.

Biotech Poised for Rebound

Biotech Poised for Rebound

If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.

Biotech Poised for Rebound

Biotech Poised for Rebound

If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.

How to Trade the Week's Most Active Stocks -- Micron, Nvidia, Synergy Pharma and More

How to Trade the Week's Most Active Stocks -- Micron, Nvidia, Synergy Pharma and More

Here's a technical look on how to trade some of the most active stocks on the market this week.

Futures Mixed Ahead of Holiday Weekend; Asia Opened Lower

Futures Mixed Ahead of Holiday Weekend; Asia Opened Lower

Futures follow market retreats as investors ponder trade and look forward to Christmas.

Synergy Pharmaceuticals Announces Positive Results In Second Phase 3 Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Synergy Pharmaceuticals Announces Positive Results In Second Phase 3 Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced positive top-line results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of plecanatide, an investigational once-daily...

First Week of February 2017 Options Trading For Synergy Pharmaceuticals (SGYP)

First Week of February 2017 Options Trading For Synergy Pharmaceuticals (SGYP)

Investors in Synergy Pharmaceuticals Inc saw new options become available this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGYP options chain for the new February 2017 contracts and identified one put and one call contract of particular interest.